Compare AbCellera Biologics Inc (ABCL) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ABRDN Physical Gold Shares ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while ABRDN Physical Gold Shares ETF trades at $38.64. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | SGOL | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $8.12 | $51.41 |
52-Week Low | $2.78 | $31.18 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SGOL, a US-listed gold ETF, trades at $39.65, up 1.04% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights central bank gold buying and shifting Fed rate expectations as key drivers. The stock lacks fundamental ratios like P/E and P/B, typical for commodity ETFs tracking physical gold prices rather than corporate earnings.
The outlook for SGOL hinges on gold's safe-haven appeal amid economic uncertainty, with analysts forecasting potential price gains to $4,600-$5,500 per ounce by 2027. Risks include Fed policy shifts, dollar strength, and volatility from geopolitical events. Investor sentiment is cautiously optimistic due to institutional accumulation and ETF inflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
